molecular targeted therapy
Oncogene addiction in gliomas: Implications for molecular targeted therapy
... for molecular targeted therapy in human ...Some molecular targeted drugs only work in a subgroup of tumor ...priate molecular targeted agent and combination ther- apy for ...
5
Challenging issues in molecular-targeted therapy
... combination therapy should induce cell cycle arrest by gene expression modulation in epithelial tumor and endothelial ...this therapy can target patients with tumors that are dependent upon VEGF, ...
8
Evaluating the evolving evidence: The challenges of molecular targeted therapy in management of gastric cancer
... Molecular-targeted therapy is changing the treatment of gastric ...mab-based therapy, the investigational angiogenesis in- hibitor ramucirumab has been shown to significantly extend survival ...
10
Molecular Targeted Therapy for Breast Cancer: A New Frontiers
... Osteoprotegerin (Fc-OPG) is an anti- RANKL therapy which inhibits bone resorption in bone metastasis. It works by neutralizing the RANKLs’ biological effects and blocking the association of RANKL or any other ...
7
MOLECULAR TARGETED THERAPY OF CANCER: THE PROGRESS AND FUTURE PROSPECT
... www.wjpr.net Vol 7, Issue 09, 2018. 143 Mechanisms of chemotherapeutics drug resistance are complex in many fields and cannot be easily solved in clinic. For example, even though numerous studies have been conducted to ...
18
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer
... Wee1 is a member of the Serine/Threonine protein kinase family and is a key regulator of cell cycle progression. It has been known that WEE1 is highly expressed and has oncogenic functions in various cancers, but it is ...
15
Apatinib for molecular targeted therapy in tumor
... outcomes were reported that mPFS and mOS were 3.3 months (95% CI: 1.7–5.0 months) and 10.6 months (95% CI: 5.6–15.7 months), respectively. In the 56 evaluable patients, overall response and clinical benefit rates were ...
7
Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
... achieved an objective response, except one patient (No. 6) who received docetaxel as second-line chemotherapy and achieved a partial response. In all patients, median PFS for first-line chemotherapy was 1.5 (95 % CI ...
7
Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
... The observation that immune response gene signatures may be associated with improved survival outcome is intriguing when considering novel immunotherapies, such as anti-CTLA4 and anti-PD1 antibodies in melanoma. Such ...
13
Updates in Genetic Molecular Targeted Therapy for Glioblastoma
... Two phase II studies were conducted to evaluate the efficacy of bevacizumab in progressive or recurrent GBM after front line standard therapy. First one conducted on 48 patients with recurrent glioblastoma to ...
15
Molecular targeted therapy for the treatment of gastric cancer
... cases were included and randomly divided into two groups based on treatment with trastuzumab plus chemotherapy (294 cases) and chemotherapy (290 cases). The results demonstrated that the efficacy end- point in the ...
11
Molecular Targeted Therapy of Hepatocellular Carcinoma
... systemic therapy with many different classes of agents for HCC has been ...key molecular pathways implicated in the pathogenesis of ...molecularly targeted agents are at different stages of clinical ...
14
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
... Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed ...first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that ...
13
Advances in the targeted therapy of liposarcoma
... Abstract: Liposarcoma (LPS) is the most common type of soft-tissue sarcoma. Complete surgical resection is the only curative means for localized disease; however, both radiation and conventional cytotoxic chemotherapy ...
12
Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment
... The PAX3-FKHR fusion gene results from a translocation between chromosomes 2 and 13 in rhabdomyosarcomas. The amino-terminal paired box and homeodomain DNA-binding domains of PAX3 are fused in frame to the COOH-terminal ...
22
RUNX2 and WWOX genes as molecular biomarkers and candidates for targeted therapy in Egyptian patients with primary conventional osteosarcoma
... the molecular pathogenesis of OS is highly required for better under- standing of tumor biology, to identify molecular prog- nostic and predictive biomarkers as well as for better selection of genes that ...
9
Complement-targeted therapy: development of C5- and C5a-targeted inhibition
... Thus, the alternative pathway of complement activation is activated in MPO- ANCA-associated nephritis, and a C5a receptor antagonist may be efficacious in treating that nephritis.. The C[r] ...
5
Mesothelin as a biomarker for targeted therapy
... Despite the fact that there are few clinical trials of MSLN-targeted vaccines and the results of these tri- als have been disappointing, many preclinical studies are still ongoing. One study showed that a ...
18
Cancer biomarkers for targeted therapy
... 15. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, ...
7
Targeted therapy in cervical cancer
... performance status was 0 (32%) or 1 (68%), median age was 45 years, the overwhelming majority (92%) had squamous carcinoma, 95% had M1 disease while 5% had recurrent disease, and 35% had received 1% and 65% had received ...
8